Peripheral nerve injury can lead to anomalous sensations referred to as neuropathic pain. Nerve injury may result from a variety of insults ranging from frank injury to the nerve though sectioning or compression, to chemotherapeutics and autoimmune conditions. Symptoms often include continuous burning pain and abnormal sensory sensations such as allodynia (pain as a result of non-noxious stimuli) and hyperalgesia (an increased response to a normally painful stimulus) Persistent pain after resolution of clinically appreciable signs of chemotherapy poses a therapeutic challenge and immunosuppressive therapies do not meet this medical need. Accordingly, novel treatment options that afford additional benefit in relief of pain are needed. In this proposal, the experienced medicinal chemistry capabilities of Epigen Biosciences Inc. will enable the discovery and development of novel small molecules with suitable drug like properties for pain. The chemistry development will be coupled with the in vitro capabilities of UC Davis Medical School to test the compounds. Lead compounds will be assessed in pain models at UCSD. The proposed project is designed to develop small molecule therapeutics for pain.

Agency
National Institute of Health (NIH)
Type
Small Business Technology Transfer (STTR) Grants - Phase I (R41)
Project #
1R41NS086244-01A1
Application #
8715453
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Oshinsky, Michael L
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Epigen Biosciences, Inc.
Department
Type
DUNS #
City
San Diego
State
CA
Country
United States
Zip Code
92121